| Domain | Evidence-backed finding | Suggested ontology/identifier | Evidence type/limitations |
|---|---|---|---|
| Disease identifiers / nomenclature | Rare autosomal recessive linkeropathy caused by biallelic **B3GAT3** variants; originally proposed as **“Larsen-like syndrome, B3GAT3 type”** and now often grouped under **B3GAT3-related disorder/linkeropathy**. MONDO association available. OMIM phenotype cited in review literature as **245600**. (pqac-00000000, pqac-00000001, pqac-00000004) | MONDO:0009511; OMIM:245600; disease label: Larsen-like syndrome, B3GAT3 type | Aggregated disease-resource plus primary case reports/reviews; naming varies across papers and severity spectrum overlaps ABS/SGS/GO-like presentations. |
| Evidence provenance | Knowledge derives from **aggregated disease-level literature and curated resources**, but core evidence is from **individual case reports/series** and small family-based cohorts, not EHR-scale datasets. (pqac-00000001, pqac-00000004, pqac-00000005) | Evidence type labels: human case report; family study; review | Very small sample sizes; ascertainment and publication bias likely. |
| Causal gene | **B3GAT3** encodes **beta-1,3-glucuronyltransferase 3 / GlcAT-I**, the enzyme that adds the terminal glucuronic acid of the common proteoglycan linker tetrasaccharide. (pqac-00000000, pqac-00000001, pqac-00000011) | HGNC gene symbol: B3GAT3; protein label: GlcAT-I | Strong gene-disease validity from multiple families, functional assays, and curated target-disease association. |
| Inheritance | **Autosomal recessive** inheritance with affected individuals typically carrying **biallelic** variants; many reported families are consanguineous. (pqac-00000001, pqac-00000003, pqac-00000004) | Inheritance term: autosomal recessive | Based on small pedigrees; penetrance appears high for biallelic pathogenic variants but is not formally quantified. |
| Pathogenic variant spectrum | Reported variants include homozygous **c.830G>A p.Arg277Gln**, **c.419C>T p.Pro140Leu**, **c.416C>T p.Thr139Met**, **c.245C>T p.Pro82Leu**, **c.667G>A p.Gly223Ser**, and compound heterozygous **c.1A>G p.Met1? / c.671T>A p.Leu224Gln**; most are missense/hypomorphic. (pqac-00000002, pqac-00000004, pqac-00000015) | Variant class labels: missense; start-loss; compound heterozygous; homozygous | Review synthesis included ~26 patients/13 families; some variants lacked direct fibroblast functional testing. |
| Core mechanism | B3GAT3 deficiency impairs completion of the **Xyl-Gal-Gal-GlcA** linker region, disrupting synthesis of **chondroitin sulfate (CS), dermatan sulfate (DS), and heparan sulfate (HS)** chains on proteoglycans. Patient fibroblasts showed markedly reduced GlcAT-I activity and reduced surface GAG chains. (pqac-00000001, pqac-00000011, pqac-00000014, pqac-00000016) | GO: glycosaminoglycan biosynthetic process; proteoglycan biosynthetic process; Golgi apparatus | Direct biochemical evidence exists for p.Arg277Gln; mechanistic extrapolation to some later variants is partly review-based. |
| Protein dysfunction / subcellular localization | GlcAT-I normally localizes to the **cis/cis-medial Golgi**; mutant p.Arg277Gln showed reduced protein abundance, loss of normal Golgi localization, and residual activity consistent with a **hypomorphic loss-of-function** effect. (pqac-00000016) | GO cellular component: cis-Golgi network / Golgi apparatus | Directly shown for one variant in fibroblasts/recombinant assays; not established for every allele. |
| Functional quantitative data | In patient fibroblasts with p.Arg277Gln, **GlcAT-I activity was reduced to ~3–5% of control**, with **CS chains ~65%** and **HS chains ~53%** of control levels. (pqac-00000016, pqac-00000014) | Laboratory phenotype labels: reduced glucuronyltransferase activity; decreased cell-surface CS/HS | Single-family biochemical dataset; no standardized clinical biomarker thresholds. |
| Genotype-phenotype correlation | Severity appears to vary by variant/domain: **p.Gly223Ser** is associated with a particularly severe infantile craniosynostosis/bone fragility phenotype; **p.Pro140Leu** may have prominent skeletal disease with less cardiac involvement. (pqac-00000003, pqac-00000004, pqac-00000011) | Genotype-phenotype association label | Correlations are suggestive only because each genotype is represented by very few patients. |
| Major phenotype group: skeletal / joints | Core musculoskeletal findings include **short stature**, **joint hypermobility/laxity**, **multiple joint dislocations**, **elbow abnormalities**, **radioulnar synostosis**, **foot deformity**, **kyphoscoliosis/scoliosis**, **osteopenia**, and sometimes **fractures**. (pqac-00000001, pqac-00000003, pqac-00000008, pqac-00000015) | HPO suggestions: Short stature; Joint hypermobility; Joint dislocation; Radioulnar synostosis; Scoliosis; Kyphosis; Osteopenia; Fractures; Talipes/clubfoot | Frequencies in reviews are variant-stratified and tiny; pooled percentages are unstable. |
| Major phenotype group: craniofacial | Frequent craniofacial features include **midface hypoplasia**, **depressed nasal bridge**, **micrognathia**, **downslanting palpebral fissures**, **short/webbed neck**, **blue sclerae**, **prominent/proptotic eyes**, and in severe cases **craniosynostosis**. (pqac-00000001, pqac-00000003, pqac-00000008, pqac-00000015) | HPO suggestions: Midface retrusion/hypoplasia; Depressed nasal bridge; Micrognathia; Downslanting palpebral fissures; Blue sclerae; Craniosynostosis; Webbed neck | Some features are concentrated in severe allelic subsets rather than universal across B3GAT3 disease. |
| Major phenotype group: cardiovascular | Cardiovascular involvement is a notable distinguishing feature, including **bicuspid aortic valve**, **mitral valve prolapse**, **septal defects**, **aortic root dilatation**, and broader congenital heart disease. (pqac-00000001, pqac-00000006, pqac-00000008) | HPO suggestions: Bicuspid aortic valve; Mitral valve prolapse; Atrial septal defect; Aortic root dilatation; Congenital heart defect | Cardiac burden appears enriched relative to some other linkeropathies, but exact prevalence remains uncertain. |
| Major phenotype group: connective tissue / skin / other | Additional reported findings include **pectus abnormality**, **peculiar fingers** (long/slender/tapered/broad/arachnodactylous), **hypotonia**, low bone mineral density, ophthalmic abnormalities, and occasional developmental delay; cognition may be normal in some families. (pqac-00000006, pqac-00000008, pqac-00000015, pqac-00000016) | HPO suggestions: Pectus excavatum/carinatum; Arachnodactyly; Hypotonia; Low bone mineral density; Strabismus; Refractive error | Heterogeneous and incompletely reported across studies. |
| Anatomy affected | Primary systems affected are **skeletal/connective tissue** and **cardiovascular**; secondary involvement can include craniofacial bones, eyes, and growth/endocrine features. (pqac-00000001, pqac-00000006, pqac-00000008) | UBERON suggestions: skeleton; joint; cartilage; heart valve; aorta; craniofacial skeleton | Organ mapping is inferred from clinical phenotypes and tissue expression rather than systematic pathology series. |
| Tissue / cell types / biological process | Relevant tissues/cells include **cartilage/chondrocytes**, **osteoblast-lineage cells**, **fibroblasts**, and **aortic/valvular connective tissues**. Mouse expression data showed B3gat3 in heart, aorta, bone, and osteoblasts. (pqac-00000016, pqac-00000019, pqac-00000020) | CL suggestions: chondrocyte; osteoblast; fibroblast. GO suggestions: extracellular matrix organization; cartilage development; skeletal system development; heart valve development; glycosaminoglycan biosynthesis | Cell-type evidence is partly indirect; human single-cell/spatial data were not found. |
| Onset / temporal development | Disease is typically **congenital or neonatal/early childhood onset** with structural anomalies apparent prenatally or at birth in severe cases and progressive orthopedic burden during childhood in survivors. (pqac-00000001, pqac-00000003, pqac-00000006) | Onset term: congenital onset / neonatal onset | Natural history remains poorly defined because of few longitudinal cohorts. |
| Diagnostics | Diagnosis currently relies on **phenotype recognition plus molecular testing** (single-gene analysis, gene panels, trio exome sequencing, or broader genomic testing), with segregation confirmation. Cardiac imaging and skeletal radiography are important supportive assessments. (pqac-00000006, pqac-00000007, pqac-00000012, pqac-00000017) | Diagnostic labels: exome sequencing; gene panel; Sanger confirmation; echocardiography; skeletal radiography | No consensus formal diagnostic criteria or validated standalone biochemical clinical test were identified. |
| Differential diagnosis | Differential diagnoses discussed in the literature include **classic Larsen syndrome**, **CHST3-related autosomal recessive Larsen syndrome**, **Antley-Bixler syndrome**, **Shprintzen-Goldberg syndrome**, **geroderma osteodysplastica**, **spondylodysplastic EDS**, **musculocontractural EDS**, **Noonan syndrome**, **Desbuquois syndrome**, and **otopalatodigital syndrome type II**. (pqac-00000007, pqac-00000012, pqac-00000014) | Differential diagnosis labels as listed | Differential framing comes from case-report clinical reasoning, not guideline-based algorithms. |
| Management / real-world implementation | Management is **supportive and multidisciplinary**: orthopedic surveillance/intervention for dislocations, scoliosis, instability, and fractures; cardiology surveillance/intervention for structural heart disease; rehabilitation/physical therapy; pain management; ophthalmology follow-up; and genetic counseling. Reported real-world interventions include **atrial septal defect repair**, pulmonary hypertension management, and **bisphosphonate treatment** for low bone mineral density in an adolescent patient. (pqac-00000006) | NCIT suggestions: Physical Therapy; Orthopedic Procedure; Cardiac Surgical Procedure; Genetic Counseling; Bisphosphonate Therapy | Evidence is limited to case-based management; no standardized treatment algorithm specific to B3GAT3 disease. |
| Pharmacotherapy / advanced therapeutics | **No disease-modifying pharmacotherapy, gene therapy, RNA therapy, or targeted molecular treatment** specific to B3GAT3-related disease was found. (pqac-00000006, pqac-00000007) | NCIT suggestions if supportive only: Bisphosphonate Therapy; Analgesic Therapy | Negative evidence based on available literature/trial search, not proof of absence of off-label use anywhere. |
| Prognosis | Prognosis is **highly variable**. Severe **p.Gly223Ser** cases showed infantile lethality, with reports that all described patients died before age 1 year; other individuals survive into adolescence/adulthood with chronic orthopedic and cardiac morbidity. (pqac-00000003, pqac-00000004, pqac-00000006) | Prognosis labels: variable severity; infantile lethal subset | No survival curves or formal prognostic models exist. |
| Epidemiology / population | Ultra-rare disorder with **no robust prevalence or incidence estimates** identified. Reported families include multiple consanguineous pedigrees; one severe recurrent variant cohort involved families of **Moroccan origin**. (pqac-00000003, pqac-00000004) | Epidemiology label: ultra-rare Mendelian disease | Published population data are case-based only; no registry-derived denominator. |
| Protective/environmental factors | **No established environmental risk factors, protective factors, or gene-environment interactions** specific to this Mendelian disorder were identified. (pqac-00000001, pqac-00000004) | Not established | Absence reflects evidence gap, not demonstrated nonexistence. |
| Clinical trials | Literature and trial search found **no disease-specific interventional clinical trials** for Larsen-like syndrome, B3GAT3 type. (pqac-00000000) | ClinicalTrials.gov / ICTRP status: none found | Search-negative result; trials could emerge later under broader linkeropathy terminology. |
| Other species / natural disease | **No confirmed naturally occurring veterinary/nonhuman disease** equivalent was identified from the retrieved evidence. (pqac-00000000) | Not established | Evidence gap; available literature focused on engineered models. |
| Model organisms | The clearest direct model is **engineered zebrafish b3gat3 mutant (b3gat3hi307)**. Mutants showed near-abolished CS production with residual HS, undersulfated CS, and abnormal pharyngeal cartilage morphology/ECM, supporting a mechanism in cartilage morphogenesis. (pqac-00000019, pqac-00000020) | Model labels: zebrafish mutant; engineered loss-of-function model | Useful mechanistically but does not capture the full human multisystem/cardiac spectrum. |
| Model-mechanism insight | Zebrafish work suggests that when linker-region biosynthesis is impaired, **HS biosynthesis is relatively prioritized over CS**, and defective CS-rich cartilage ECM contributes to malformed cartilage. (pqac-00000019, pqac-00000020) | GO suggestions: cartilage morphogenesis; extracellular matrix assembly; heparan sulfate/chondroitin sulfate biosynthesis | Model inference; not directly measured in human tissues beyond fibroblast GAG assays. |
| Recent developments (2023-2024) | No major new disease-specific patient cohort or therapy was found in 2023-2024 from the retrieved search. The main recent advance is a **2024 pathway-level model** emphasizing flux between HSPG/CSPG biosynthesis and how linkeropathy phenotypes may arise from preferential HSPG over CSPG production. (pqac-00000000) | Pathway label: HSPG/CSPG biosynthesis model | Recent literature is mainly review/conceptual rather than new clinical intervention evidence. |


*Table: This compact table summarizes the main evidence-backed knowledge-base facts for Larsen-like syndrome, B3GAT3 type, including identifiers, mechanism, phenotype spectrum, diagnosis, management, prognosis, and models. It also highlights key limitations: very small family-based cohorts, unstable frequency estimates, and the absence of disease-modifying therapy or disease-specific trials.*